title: Remifentanil reversibly abolished phrenic long term facilitation in rats subjected to acute intermittent hypoxia.
abstract: The aim was to investigate whether intravenous infusion of remifentanil would depress phrenic long term facilitation (pLTF) evoked by acute intermittent hypoxia (AIH) in adult, male, urethane anaesthetized Sprague-Dawley rats, bilaterally vagotomized, paralyzed and mechanically ventilated. The experimental group received a remifentanil infusion (0.5 μg/kg/min i.v., n=12), whereas the control group (n=6) received saline. Rats were exposed to AIH protocol. Phrenic nerve amplitude (PNA), burst frequency (f) and breathing rhythm parameters (Ti, Te, Ttot) were analyzed during 5 hypoxias and at 15, 30, and 60 minutes after the final hypoxia, and compared to baseline values. At the end of the experiment, the infusion of remifentanil was stopped and phrenic nerve activity was compared to baseline values prior to remifentanil infusion. In the control group, peak phrenic nerve activity (pPNA) significantly increased at 60 min (T60, increase by 138.8±28.3%, p=0.006) after the last hypoxic episode compared to baseline values, i.e. pLTF was induced. In remifentanil treated rats, there were no significant changes in peak phrenic nerve activity at T60 compared to baseline values (decrease by 5.3±16.5%, p>0.05), i.e. pLTF was abolished. Fifteen minutes following cessation of remifentanil infusion, pPNA increased by 93.2±40.2% (p<0.05) and remained increased compared to pre-remifentanil-infusion values for more than 30 minutes, i.e. pLTF could be observed after cessation of the remifentanil infusion. In conclusion, the short acting μ-opioid receptor agonist, remifentanil, reversibly abolished phrenic long term facilitation in urethane anesthetized rats.
authors.affiliation: Department of Anesthesiology and Intensive Care, University Hospital Split, Split, Croatia. maja.valic@mefst.hr.
authors.forename: B
authors.initials: B
authors.lastname: Ivancev
authors.forename: M
authors.initials: M
authors.lastname: Carev
authors.forename: R
authors.initials: R
authors.lastname: Pecotic
authors.forename: M
authors.initials: M
authors.lastname: Valic
authors.forename: I
authors.initials: I
authors.lastname: Pavlinac Dodig
authors.forename: N
authors.initials: N
authors.lastname: Karanovic
authors.forename: Z
authors.initials: Z
authors.lastname: Dogas
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D000860:Hypoxia / Q000503:physiopathology*; D017774:Long-Term Potentiation / Q000187:drug effects; D008297:Male; D010791:Phrenic Nerve / Q000187:drug effects* / Q000502:physiology; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077208:Remifentanil
chemical_list: D000701:Analgesics, Opioid; D006993:Hypnotics and Sedatives; D010880:Piperidines; D000077208:Remifentanil